Arcus Biosciences: Funding, Investors & Team (Oct 2026)
Arcus Biosciences is a biopharmaceutical company specializing in oncology, dedicated to discovering, developing, and selling innovative cancer treatments. The company focuses on using new insights in immunology to create new therapies for cancer. Arcus has several molecules in various stages of clinical development, including Etrumadenant (AB928), the first dual A2a/A2b adenosine receptor antagonist in clinical trials for multiple types of cancer. They also have AB680, the first small-molecule CD73 inhibitor in clinical development for pancreatic cancer treatment. Additionally, they are working on Domvanalimab (AB154), an anti-TIGIT monoclonal antibody, and AB308, an anti-TIGIT antibody, both being investigated for different types of cancer. Zimberelimab (AB122), their anti-PD-1 monoclonal antibody, is being explored in combination regimens. The company was founded in 2015 in Hayward, California by Terry Rosen and Juan Jaen.
Arcus Biosciences has raised $150M across 1 funding round on record, the most recent an undisclosed round of $150M announced in Feb 2025.
That round is above the $8.1M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Arcus Biosciences Company Profile and Key Stats
Latest funding round on record: Feb 2025.
Arcus Biosciences Funding Rounds
Arcus Biosciences Founders and Leadership Team
No contact details are on record for this team yet.
Arcus Biosciences Funding Compared to Other Biotechnology Startups
Arcus Biosciences' latest round of $150M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Arcus Biosciences in Biotechnology and Hayward
Companies Similar to Arcus Biosciences
Kallyope, we believe that the gut is the gateway to our internal world. Containing millions of neurons, the…
Astrocyte Pharmaceuticals is a drug development company that helps in the recovery and well-being of brain…
Tiny Health offers a gut health test specifically designed for mothers and babies aged 0 to 3 years.…
Junevity is dedicated to using cutting-edge transcription factor medicines to combat age-related diseases.…
Arkea Bio creates technology aimed at reducing greenhouse gas (GHG) emissions in the agricultural sector.
Serán is a contract development and manufacturing organization providing a comprehensive suite of…
Precision’s goal is to provide breakthrough treatments for the one billion patients worldwide suffering from…
Enveda is a biotechnology company that utilizes AI-powered tools to explore and characterize molecules from…
Avery Therapeutics, Inc. is a company dedicated to developing tissue engineered therapeutics to treat…
Circle Pharma is a biotechnology company in the initial stages of development that uses unique computational…
Evvy is for people with vaginas who want to be empowered with information about their microbiome. Their…
Arcus Biosciences Funding FAQs
What does Arcus Biosciences do?
Arcus Biosciences is a biopharmaceutical company specializing in oncology, dedicated to discovering, developing, and selling innovative cancer treatments. The company focuses on using new insights in immunology to create new therapies for cancer. Arcus has several molecules in various stages of clinical development, including Etrumadenant (AB928), the first dual A2a/A2b adenosine receptor antagonist in clinical trials for multiple types of cancer. They also have AB680, the first small-molecule CD73 inhibitor in clinical development for pancreatic cancer treatment. Additionally, they are working on Domvanalimab (AB154), an anti-TIGIT monoclonal antibody, and AB308, an anti-TIGIT antibody, both being investigated for different types of cancer. Zimberelimab (AB122), their anti-PD-1 monoclonal antibody, is being explored in combination regimens. The company was founded in 2015 in Hayward, California by Terry Rosen and Juan Jaen.
How much funding has Arcus Biosciences raised?
Arcus Biosciences has raised $150M across 1 round on record. The most recent is an undisclosed round of $150M announced in Feb 2025.
When did Arcus Biosciences last raise funding?
Arcus Biosciences' most recent funding round on record is an undisclosed round of $150M, announced in Feb 2025.
Who founded Arcus Biosciences?
FundedIQ lists Terry Rosen (Founder) at Arcus Biosciences.
Where is Arcus Biosciences headquartered?
Arcus Biosciences is based in Hayward, California, United States.
How many employees does Arcus Biosciences have?
Arcus Biosciences is in the 101-250 employee band.
How does Arcus Biosciences' funding compare to other Biotechnology startups?
Arcus Biosciences' latest round of $150M is above the $8.1M median round size for Biotechnology companies on FundedIQ across 4,185 tracked companies over the last two years.
About FundedIQ's Arcus Biosciences Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Arcus Biosciences is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.
Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.